Güner, Gürkan

Profile Picture
Profile URL
https://hdl.handle.net/20.500.14365/7528
Name Variants
Guner, Gurkan
Guner, G.
Guner, Guerkan
Job Title
Email Address
gurkan.guner@ieu.edu.tr
gunergurkan@yahoo.com
Main Affiliation
09.02. Internal Sciences
Status
Current Staff
Website
ORCID ID
0000-0003-2275-1158
Scopus Author ID
57200544019
Turkish CoHE Profile ID
C934744929A21D2C
Google Scholar ID
L8Putx4AAAAJ
WoS Researcher ID
I-9062-2013
Files
GurkanGuner.jpg (6.55 KB)

Sustainable Development Goals

NO POVERTY1
NO POVERTY
0
Research Products
ZERO HUNGER2
ZERO HUNGER
0
Research Products
GOOD HEALTH AND WELL-BEING3
GOOD HEALTH AND WELL-BEING
2
Research Products
QUALITY EDUCATION4
QUALITY EDUCATION
0
Research Products
GENDER EQUALITY5
GENDER EQUALITY
0
Research Products
CLEAN WATER AND SANITATION6
CLEAN WATER AND SANITATION
0
Research Products
AFFORDABLE AND CLEAN ENERGY7
AFFORDABLE AND CLEAN ENERGY
0
Research Products
DECENT WORK AND ECONOMIC GROWTH8
DECENT WORK AND ECONOMIC GROWTH
0
Research Products
INDUSTRY, INNOVATION AND INFRASTRUCTURE9
INDUSTRY, INNOVATION AND INFRASTRUCTURE
0
Research Products
REDUCED INEQUALITIES10
REDUCED INEQUALITIES
0
Research Products
SUSTAINABLE CITIES AND COMMUNITIES11
SUSTAINABLE CITIES AND COMMUNITIES
0
Research Products
RESPONSIBLE CONSUMPTION AND PRODUCTION12
RESPONSIBLE CONSUMPTION AND PRODUCTION
0
Research Products
CLIMATE ACTION13
CLIMATE ACTION
0
Research Products
LIFE BELOW WATER14
LIFE BELOW WATER
0
Research Products
LIFE ON LAND15
LIFE ON LAND
0
Research Products
PEACE, JUSTICE AND STRONG INSTITUTIONS16
PEACE, JUSTICE AND STRONG INSTITUTIONS
0
Research Products
PARTNERSHIPS FOR THE GOALS17
PARTNERSHIPS FOR THE GOALS
0
Research Products
Documents

26

Citations

159

h-index

7

Go to Scopus profile
Documents

25

Citations

136

Go to WoS profile
Scholarly Output

6

Articles

4

Views / Downloads

19/31

Supervised MSc Theses

0

Supervised PhD Theses

0

WoS Citation Count

7

Scopus Citation Count

7

Patents

0

Projects

0

WoS Citations per Publication

1.17

Scopus Citations per Publication

1.17

Open Access Source

5

Supervised Theses

0

JournalCount
Annals of the Rheumatıc Dıseases2
Cancers1
Eskisehir Medical Journal (Online)1
Expert Opinion on Pharmacotherapy1
Turkish Journal of Gastroenterology1
Current Page: 1 / 1

Scopus Quartile Distribution

Competency Cloud

GCRIS Competency Cloud

Filters

2018 - 201922020 - 20264
Reset filters

Settings

Scholarly Output Search Results

Now showing 1 - 6 of 6
  • Thumbnail Image
    Conference Object
    Molecular Mechanisms Mediating Antioxidant Effect of Epigallocatechin-3 in Experimental Scleroderma Model
    (Bmj Publishing Group, 2018-06) Kocak, A.; Harmanci, D.; Birlik, M.; Guner, G.
    [Abstract Not Available]
  • Thumbnail Image
    Article
    Metastatik Mide Kanserli Geriatrik Hastalarda İkili ve Üçlü Kemoterapi Rejimlerinin Karşılaştırılması
    (2025-07-10) Ürün, Yonca Yılmaz; Guner, Gurkan; Dirik, Yaren; Urun, Muslih; Cesur, Selcan; Oflas, Nur Düzen
    Giriş: Yaşlı metastatik mide kanseri hastalarının yönetimi için kılavuz eksikliği bulunmaktadır. Bu çalışmanın amacı, metastatik mide kanserli yaşlı hastaların birinci basamak tedavisinde ikili ve üçlü kemoterapi rejimlerinin etkinliğini ve yan etkilerini karşılaştırmaktır. Yöntemler: Van Yüzüncü Yıl Üniversitesi Tıp Fakültesi'nde 2011-2021 yılları arasında tedavi edilen geriatrik metastatik mide kanseri hastaları retrospektif olarak değerlendirildi. Demografik özellikler, tedavi rejimleri ve yanıtlar, grade 3-4 toksisite, progresyonsuz sağkalım (PFS) ve genel sağkalım (OS) uygun istatistiksel yöntemlerle analiz edildi. Bulgular: Hastaların ortalama yaşı 73,8±3,6 idi. Çalışmaya dahil edilen 224 hastanın 56'sı (%25) kadındı. Hastaların 99'una (%44,2) ikili kemoterapi rejimi uygulanırken, 125'ine (%55,8) üçlü kemoterapi rejimi uygulandı. Ortanca OS, ikili grupta 9,8 ay ve üçlü grupta 10,1 aydı (p=0,954). Ortanca PFS sırasıyla ikili grubunda 5,8 ay ve üçlü grupta 6,2 aydı (p=0,935). Advers olay oranları açısından gruplar arasında istatistiksel olarak anlamlı bir fark bulunmamıştır. Sonuç: Bu çalışmada, üçlü kemoterapinin ek toksisiteye neden olmadığı ancak sağkalımı da önemli ölçüde iyileştirmediği bulunmuştur. Bu nedenle, geriatrik popülasyonda daha düşük toksisiteye sahip olabilecek ikili rejimler tercih edilebilir.
  • Thumbnail Image
    Article
    Vincamine Mitigates Methotrexate-Induced Liver Fibrosis Model
    (AVES, 2025-06-23) Urun, Yonca Yilmaz; Guner, Gurkan; Bora, Ejder Saylav; Taskin, Ayse Buket; Urun, Muslih; Erbas, Oytun
    Background/Aims: Liver fibrosis is linked to higher rates of death and disease. This study examined the hepatoprotective properties of vincamine and its potential therapeutic application in treating liver damage caused by methotrexate in rats. Materials and Methods: Thirty male Wistar albino rats, with weights ranging from 150 to 200 g and ages between 10 and 12 weeks, were included in the study. A total of 10 rats were selected to serve as the control group, receiving no medication. A group of 20 rats was given a single intraperitoneal dose of 20 mg/kg methotrexate in order to cause liver damage. Subsequently, the participants were randomly allocated into 2 cohorts and administered either 1 mL/kg/day tap water or 50 mg/kg/day vincamine orally through gavage on a daily basis for a duration of 10 days. Following the completion of the treatment period, the animals were euthanized and their livers were examined histologically. Furthermore, the levels of plasma galectin-3 (gal-3), cytokeratin 18, malondialdehyde (MDA), alanine transaminase (ALT), liver MDA, and transforming growth factor beta (TGF-beta) levels were evaluated. Results: Treatment with vincamine resulted in a significant decrease in plasma gal-3, cytokeratin, MDA, and ALT levels and liver MDA and TGF-beta levels compared to the methotrexate and saline group. Vincamine treatment effectively protected against liver injury, and histopathological examination of the livers confirmed these results. Conclusion: This study demonstrates that vincamine alleviates methotrexate-induced liver toxicity via exhibiting antioxidant, antiinflammatory, and anti-fibrotic activities and improved liver functionally, biochemically, and histopathologically.
  • Thumbnail Image
    Article
    Citation - WoS: 7
    Citation - Scopus: 7
    Sonographic Measurements of Rectus Femoris Muscle Thickness Strongly Predict Neutropenia in Cancer Patients Receiving Chemotherapy
    (MDPI, 2024-03-05) Güner, Gürkan; Özçakar, Levent; Baytar, Yusuf; Onur, Mehmet Ruhi; Demir, Metin; Aktas, Burak Yasin; Aktepe, Oktay Halit; Dizdar, Omer
    The objective of this study was to explore the possible association between low skeletal muscle mass (SMM)-assessed by computed tomography (CT) and ultrasound (US)-and hematologic toxicity in cancer patients. A prospective cohort study was conducted in cancer patients who received anthracycline-based chemotherapy between 2018 and 2020 and who had baseline abdominal CT including L3 level for measuring SMM. Regional muscle measurements were carried out using US. A total of 65 patients (14 males, 51 females) were included. ROC (receiver operating characteristic) analysis identified threshold values of 18.0 mm [AUC (area under the curve) = 0.765] for females and 20.0 mm (AUC = 0.813) for males, predicting severe neutropenia. Using these cut-offs, females with low rectus femoris (RF) thickness (<18.0 mm) had a significantly higher incidence of grade >= 3 neutropenia (50.0% vs. 10.8%, p = 0.005), and males with low RF values (<20.0 mm) had a higher incidence (80.0% vs. 22.2%, p = 0.063). A regression analysis, irrespective of age, gender, and body mass index, revealed that only low RF muscle thickness increased the risk of grade 3-4 neutropenia by 9.210 times (95% CI = 2.401-35.326, p = 0.001). Utilizing US to measure RF muscle thickness aids in identifying cancer patients at an elevated risk of developing neutropenia. Needless to say, US can serve as a convenient and easily accessible tool for assessing low SMM, providing repeat point-of-care evaluations in clinical practice.
  • Thumbnail Image
    Article
    Evaluation of Novel Treatments for Metastatic Castration-Resistant Prostate Cancer
    (Taylor & Francis Ltd, 2026-03-04) Arslan, Cagatay; Guner, Gurkan
    IntroductionMetastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease with a median overall survival of approximately 2 years. Although major therapeutic advances have been achieved over the past two decades, many effective treatments have shifted to earlier disease settings, and significant unmet needs persist in the mCRPC population.Areas coveredThis narrative review is based on a structured literature search of PubMed/MEDLINE and Embase covering publications from January 2020 to October 2025, supplemented by ClinicalTrials.gov and major oncology congress abstracts (ASCO and ESMO). The molecular landscape of mCRPC, currently approved therapies, and emerging treatment strategies are discussed, including next-generation androgen receptor-targeted agents, PTEN/PI3K/AKT/mTOR pathway inhibitors, PSMA-targeted radioligand therapies, antibody-drug conjugates, CDK4/6 inhibitors, epigenetic modifiers, and novel immunotherapeutic approaches.Expert opinionThe therapeutic landscape of mCRPC has expanded substantially; however, treatment resistance and the absence of validated sequencing strategies continue to pose major challenges. Advancements in this field will rely on improved molecular profiling, biologically rational combination strategies, and the incorporation of predictive biomarkers to enable personalized treatment decisions. Concurrently, earlier integration of targeted therapies, radioligand approaches, and biomarker-enriched clinical trial designs is likely to reshape treatment paradigms and enhance long-term clinical outcomes.
  • Thumbnail Image
    Conference Object
    VITAMIN D AND VITAMIN D RECEPTOR IN PATIENTS WITH SCLERODERMA SUBTYPES
    (Bmj Publishing Group, 2018-06) Kocak, A.; Harmanci, D.; Birlik, M.; Guner, G.
    [Abstract Not Available]